A novel plant sesquiterpene lactone derivative, DETD-35, Suppresses BRAFV600E mutant melanoma growth and overcomes acquired vemurafenib resistance in mice

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1163-1176

  Feng, Jia Hua ^a,b   Nakagawa Goto, Kyoko ^c,d   Lee, Kuo Hsiung ^d   Shyur, Lie Fen ^a,e  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c KANAZAWA UNIVERSITY   (Japan)

^d University of North Carolina   (United States)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; DEOXYELEPHANTOPIN; INDOLE DERIVATIVE; LACTONE; SESQUITERPENE; SULFONAMIDE; VEMURAFENIB;

ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; MELANOMA; MOUSE; MUTATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; LACTONES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MOLECULAR STRUCTURE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SESQUITERPENES; SKIN NEOPLASMS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971543817     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0973     Document Type: Article

References (36)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
3. Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008;8:419-26.
4. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic BRAF kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med 2011;364:2507-16.
6. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies BRAFV600E amplification-mediated acquired BRAF inhibitor resistance. Nat Commun 2012;3:724.
7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to BRAFV600E inhibition by RTK or NRAS upregulation. Nature 2010;468:973-7.
8. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.
9. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
10. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human BRAFV600E mutant melanoma. J Biol Chem 2012;287:28087-98.
11. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
12. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364:772-4.
13. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 2011;13:1132-42.
14. Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. Am Soc Clin Oncol Educ Book 2013;33:e80-82.
15. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-82.
16. Curti BD. Rapid evolution of combination therapy in melanoma. N Engl J Med 2014;371:1929-30.
17. Smyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 2014;13: 2793-804.
18. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAFV600E mutations. N Engl J Med 2012;367:1694-703.
19. Huang CC, Lo CP, Chiu CY, Shyur LF. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice. Br J Pharmacol 2010;159: 856-71.
20. Huang CC, Lin KJ, Cheng YW, Hsu CA, Yang SS, Shyur LF. Hepatoprotective effect and mechanistic insights of deoxyelephantopin, a phyto-sesquiterpene lactone, against fulminant hepatitis. J Nutr Biochem 2013;24:516-530.
21. Lee WL, Wen TN, Shiau JY, Shyur LF. Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells. J Proteome Res 2010;9:237-53.
22. Lee WL, Shyur LF. Deoxyelephantopin impedes mammary adenocarcinoma cell motility by inhibiting calpain-mediated adhesion dynamics and inducing reactive oxygen species and aggresome formation. Free Radic Biol Med 2012;8:1423-36.
23. Kabeer FA, Sreedevi GB, Nair MS, Rajalekshmi DS, Gopalakrishnan LP, Kunjuraman S, et al. Antineoplastic effects of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, on lung adenocarcinoma (A549) cells. J Integr Med 2013;11:269-77.
24. Su M, Chung HY, Li Y. Deoxyelephantopin from Elephantopus scaber L. induces cell-cycle arrest and apoptosis in the human nasopharyngeal cancer CNE cells. Biochem Biophys Res Commun 2011;411:342-7.
25. Geetha BS, Nair MS, Latha PG, Remani P. Sesquiterpene lactones isolated from Elephantopus scaber L. inhibits human lymphocyte proliferation and the growth of tumour cell lines and induces apoptosis in vitro. J Biomed Biotechnol 2012;2012:721285.
26. Nakagawa-Goto K, Chen JY, Cheng YT, Lee YL, Takeya M, Saito Y, et al. Novel sesquiterpene lactone analogues as potent anti-breast cancer agents. Mol Oncol 2016 March 25. http://dx.doi.org/10.1016/j.molonc.2016.03.002. [Epub ahead of print].
27. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
28. Chou TC. Drugcombination studies andtheirsynergyquantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
29. Shyur LF, Chen CH, Lo CP, Wang SY, Kang PL, Sun SJ, et al. Induction of apoptosis in MCF-7 human breast cancer cells by phytochemicals from Anoectochilus formosanus. J Biomed Sci 2004;11:928-39.
30. Chiang YM, Lo CP, Chen YP, Wang SY, Yang NS, Kuo YH, et al. Ethyl caffeate suppresses NFkB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin. Br J Pharmacol 2005;146:352-63.
31. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-27.
32. Hsan KM, Chen CC, Shyur LF. Current research and development of chemotherapeutic agents for melanoma. Cancers (Basel) 2010;2:397-419.
33. Michielin O, Hoeller C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev 2015;41:660-70.
34. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013; 3:158-67.
35. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20:1965-77.
36. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109.